Regression of fibrous dysplasia in response to denosumab therapy: a report of two cases

Meier, M.E.; Bruggen, W. van der; Sande, M.A.J. van de; Appelman-Dijkstra, N.M. (2021)

Article / Letter to editor

We present two patients with fibrous dysplasia who showed a decrease in lesional size and activity after denosumab therapy. Both patients also experienced a reduction in pain and bone turnover markers, which had not been accomplished during previous bisphosphonate therapy. These cases highlight the potential of denosumab to decrease lesional size in fibrous dysplasia. This finding has been reported in mice, but not in humans. Denosumab may be considered when bisphosphonates are not tolerated or not effective (enough), or in severe cases as neoadjuvant therapy to improve surgical possibilities and outcome. In addition, these results show that Na[F-18]F PET-CT is suitable for detecting change in each fibrous dysplasia lesion distinctively.

• Fibrous dysplasia
• McCune Albright syndrome
• Denosumab
• Antiresorptive
• Nuclear imaging

• All authors: Meier, M.E.; Bruggen, W. van der; Sande, M.A.J. van de; Appelman-Dijkstra, N.M.
• Date: 2021-06-01
• Journal: BONE REPORTS
• Volume: 14
• DOI: doi:10.1016/j.bonr.2021.101058
• Link: https://www.sciencedirect.com/science/article/pii/S2352187221003132?via%...